
    
      This is a Phase-1, single center, randomized, double-blind, active and placebo-controlled
      study in approximately 40 healthy adult subjects.

      All subjects will remain in the Early Phase Research Unit (EPRU) for 5 days and return to the
      research facility for a Day 9 follow-up visit. Subjects will also receive a phone call on Day
      30 (Â±3 days) to assess safety.
    
  